NCT07002723 Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality
| NCT ID | NCT07002723 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Shenzhen Hospital |
| Condition | Hip Fractures |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2025-06-20 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2025-06-20 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Eligible patients are randomly divided into experimental and control groups； 2. The experimental group is given esketamine combined with dexmedetomidine，while the control group is given normal saline； 3. The patients' sleep, pain, and cognition are followed up after surgery.
Eligibility Criteria
Inclusion Criteria: * Age≥ 65 years old; * Hip fracture surgery under neuraxial anesthesia; * Signed informed consent. Exclusion Criteria: * ASA classification≥ Class V; * Presence of neuraxial anesthesia contraindications: coagulation dysfunction, thrombocytopenia, neuraxial mass, puncture site infection, etc.; * Patients with contraindications to esketamine (such as allergies, intracranial aneurysms, hyperthyroidism and glaucoma); * Patients with contraindications to dexmedetomidine (allergies); * Patients with severe cardiovascular diseases such as sick sinus syndrome, severe sinus bradycardia (heart rate \< 50 beats/min), atrioventricular block grade II or above without pacemaker, unstable angina, severe valvular heart disease, severe arrhythmia, severe macrovascular disease with New York Heart Association class III patients, etc.; * Obstructive sleep apnea syndrome (STOP-BANG score \> 3 points); * Patients with severe hepatic and renal insufficiency (such as Child-Pugh score III, creatinine clearance \< 35 mL/min, preoperative dialysis); * Those who have delirium, dementia, moderate to severe cognitive dysfunction and psychiatric disorders before the start of the trial and are unable to communicate and cooperate with the investigator.
Contact & Investigator
Tao Luo, MD,PhD
PRINCIPAL INVESTIGATOR
Peking University Shenzhen Hospitai
Frequently Asked Questions
Who can join the NCT07002723 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Hip Fractures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07002723 currently recruiting?
Yes, NCT07002723 is actively recruiting participants. Contact the research team at luotao_wh@yahoo.com for enrollment information.
Where is the NCT07002723 trial being conducted?
This trial is being conducted at Shenzhen, China.
Who is sponsoring the NCT07002723 clinical trial?
NCT07002723 is sponsored by Peking University Shenzhen Hospital. The principal investigator is Tao Luo, MD,PhD at Peking University Shenzhen Hospitai. The trial plans to enroll 96 participants.